profile of Marty in a blaser

Martin J. Blaser, MD

Director of CABM

Henry Rutgers Chair of the Human Microbiome

Departments of Medicine and Pathology & Laboratory Medicine
RBHS, Robert Wood Johnson Medical School


B.A. Economics, University of Pennsylvania, 1969
M.D. New York University School of Medicine, 1973


Martin J. Blaser holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University, where he also serves as Professor of Medicine and Pathology & Laboratory Medicine, and as Director of the Center for Advanced Biotechnology and Medicine.  Previously, he served as Chair of the Department of Medicine at New York University. A physician and microbiologist, Dr. Blaser has been studying the relationships we have with our persistently colonizing bacteria. His work over 30 years focused on Campylobacter species and Helicobacter pylori, which also are model systems for understanding the interactions of residential bacteria with their hosts. Over the last 20 years, he has also been actively studying the relationship of the human microbiome with health and important diseases including asthma, obesity, diabetes, and cancer. Dr. Blaser has served as the advisor to many students, post-doctoral fellows, and junior faculty. He currently serves as Chair of the Presidential Advisory Council for Combating Antibiotic Resistant Bacteria (PACCARB). He holds 28 U.S. patents, and has authored over 600 original articles. He wrote Missing Microbes, a book targeted to general audiences, now translated into 20 languages.

Research Focus

Microbiome studies

Professor of Medicine and Pathology & Laboratory Medicine, RWJMS

Professor of Epidemiology & Biostatistics, School of Public Health

Administrative Appointments

Director, Center for Advanced Biotechnology and Medicine

National Academy of Medicine

American Academy of Arts and Sciences

Oswald Avery Award

Alexander Fleming Award

Robert Koch Award

Present: Chair, Presidents Advisory Council for Combating Antibiotic Resistant Bacteria (PACCARB)


Past: Board of Governors American Academy of Microbiology

National Cancer Institute Board of Scientific Counselors (Chair)

NIH Advisory Board for Clinical Research (Chair)

Infectious Diseases Society of America (President)

Cho I, Yamanishi S, Cox L, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621-6. doi:10.1038/nature11400.
Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014;158(4):705-721. doi:10.1016/j.cell.2014.05.052.
Schulfer AF, Battaglia T, Alvarez Y, et al. Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nature microbiology. 2018;3(2):234-242. doi:10.1038/s41564-017-0075-5.
Blaser MJ. The Past and Future Biology of the Human Microbiome in an Age of Extinctions. Cell. 2018;172(6):1173-1177. doi:10.1016/j.cell.2018.02.040.
Zhang X-S, Li J, Krautkramer KA, et al. Antibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunity. eLife. 2018;7. doi:10.7554/eLife.37816.
Bello MGD, Knight R, Gilbert JA, Blaser MJ. Preserving microbial diversity. Science (New York, N.Y.). 2018;362(6410):33-34. doi:10.1126/science.aau8816.
Roubaud-Baudron C, Ruiz VE, Swan A, et al. Long-Term Effects of Early-Life Antibiotic Exposure on Resistance to Subsequent Bacterial Infection. mBio. 2019;10(6). doi:10.1128/mBio.02820-19.
Zhang X-S, Yin Y, Wang J, et al. Maternal cecal microbiota transfer rescues early-life antibiotic-induced enhancement of type 1 diabetes in mice. Cell host & microbe. 2021;29(8):1249-1265.e9. doi:10.1016/j.chom.2021.06.014.
Volkova A, Ruggles K, Schulfer A, Gao Z, Ginsberg S, Blaser MJ. Effects of early-life penicillin exposure on the gut microbiome and frontal cortex and amygdala gene expression. iScience. 2021;24(7):102797. doi:10.1016/j.isci.2021.102797.
Zhang X, Borbet TC, Fallegger A, Wipperman M, Blaser MJ, Müller A. An Antibiotic-Impacted Microbiota Compromises the Development of Colonic Regulatory T Cells and Predisposes to Dysregulated Immune Responses. mBio. 2021;12(1). doi:10.1128/mBio.03335-20.
Aversa Z, Atkinson E, Schafer M, et al. Association of Infant Antibiotic Exposure With Childhood Health Outcomes. Mayo Clinic proceedings. 2021;96(1):66-77. doi:10.1016/j.mayocp.2020.07.019.
Borbet TC, Pawline MB, Li J, et al. Disruption of the early-life microbiota alters Peyer’s patch development and germinal center formation in gastrointestinal-associated lymphoid tissue. iScience. 2023;26:106810. doi:
Ghaddar B, Blaser MJ, De S. Denoising sparse microbial signals from single-cell sequencing of mammalian host tissues. Nature computational science. 2023;3(9):741-747. doi:10.1038/s43588-023-00507-1.
Armstrong A, Horton D, Andrews T, et al. Saliva microbiome in relation to SARS-CoV-2 infection in a prospective cohort of healthy US adults. EBioMedicine. 2023;94:104731. doi:10.1016/j.ebiom.2023.104731.
Natanov D, Avihai B, McDonnell E, et al. Predicting COVID-19 prognosis in hospitalized patients based on early status. mBio. 2023;14:01508-23. doi:10.1128/mbio.01508-23.